Genetic Predisposition of Breast Cancer in the United Arab Emirates

This is a contemporary review of risk factors and genetic predisposition associated with breast cancer in men. The workup and evaluation of breast masses and surgical management of cancer in this population are detailed. In addition, systemic therapies for the treatment of breast cancer in men are reviewed and compared with the therapeutic approaches used for women. This reviews contains 5 figures, 2 tables and 50 references. Key words: breast-conserving surgery, chemotherapy, endocrine therapy, genetic predisposition testing, genomic profiling, lymphadenectomy, male breast cancer, mastectomy, radiotherapy, sentinel lymph node biopsy

Download Full-text

Management of the Patient with a Genetic Predisposition for Breast Cancer

Management of Breast Diseases ◽

10.1007/978-3-540-69743-5_29 ◽

2010 ◽

pp. 551-568

Author(s):

Vickie L. Venne ◽

Saundra S. Buys

Keyword(s):

Breast Cancer ◽

Genetic Predisposition

Download Full-text

Suggested modifications in the management of breast cancer patients in the era of COVID-19 pandemic: a web-based survey. (Preprint)

10.2196/preprints.27073 ◽

2021 ◽

Author(s):

Shereef Elsamany ◽

Mohamed Elbaiomy ◽

Ahmed Zeeneldin ◽

Emad Tashkandi ◽

Fayza Hassanin ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

United Arab Emirates ◽

Hormonal Therapy ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Web Based ◽

Cancer Management ◽

Breast Cancer Management ◽

Positive Breast Cancer

BACKGROUND Management of cancer patients in the current era of COVID-19 pandemic poses a significant challenge on health care systems. OBJECTIVE We explored the views of oncologists for the management of breast cancer patients during COVID-19 pandemic. METHODS A web-based questionnaire using SurveyMonkey was submitted to licensed oncologists involved in breast cancer management in Saudi Arabia, Egypt and United Arab Emirates. The survey focused on characteristics of participants, infection risk among cancer patients and possible treatment modifications related to different types of breast cancer RESULTS The survey was completed by 82 participants. For early HR positive, HER2-negative breast cancer,74.4% supported using neoadjuvant hormonal therapy in selected patients, and 58.0% preferred giving 6 over 8 cycles of adjuvant chemotherapy when indicated. Only 42.7% preferred CDK4/6 inhibitor with hormonal therapy as first line in all patients with metastatic HR-positive disease. 67.1% of participants supported using adjuvant trastuzumab for 6 instead of 12 months in selected patients with HER2-positive breast cancer. For metastatic HER2-positive, HR-positive breast cancer, 80.5% of participants supported the use of hormonal therapy with dual anti-HER2 blockade in selected patients. The preferred choice of 1st line treatment in metastatic triple negative patients with BRCA mutation and PDL1<1%, was PARP inhibitor according to 42.5% of the participants, and atezolizumab with nabpaclitaxel if the PDL1>1% according to 70.4% of the participants. CONCLUSIONS Several modifications in breast cancer management is supported by the survey participants. These modifications need to be discussed on local basis taking into account the local infrastructure and available resources. CLINICALTRIAL none

Download Full-text